Biogen (BIIB) Tops Q3 EPS by 71c, Updates Guidance, Approves $5 Billion Buyback
(Updated - October 21, 2020 7:06 AM EDT)
Biogen (NASDAQ: BIIB) reported Q3 EPS of $8.84, $0.71 better than the analyst estimate of $8.13. Revenue for the quarter came in at $3.38 billion versus the consensus estimate of $3.35 billion.
Biogen sees FY2020 EPS of $32.50-$33.50, versus the consensus of $34.77.
- Company announces new $5.0 billion share repurchase authorization
For earnings history and earnings-related data on Biogen (BIIB) click here.